1. In Vivo

Gene Therapy Manufacturers Are Highly Sought Acquisition Targets

Scale And Outsourcing Demands Lead To A Spree In Acquisitions

 
• By Amanda Micklus

Given the transformative nature of regenerative medicines, treatments yielding greatly improved patient responses that now exist as viable products on the market, cell and gene drug developers over the past several years have been drawing deal attention. Not only through collaborative partnerships, but also as acquisition targets.

Manufacturing_science-lab
For cell and gene therapies 'process is the product' • Source: Shutterstock

In 2019, attention-grabbing headlines such as Roche’s acquisition of Spark Therapeutics Inc. for $4.8bn, Biogen Inc.’s $877m play for Nightstar Therapeutics PLC, and Vertex Pharmaceuticals Inc.’s double deals for Exonics Therapeutics Inc. (up to $1bn) and Semma Therapeutics Inc. ($950m) exemplify the demand to enter or expand in this sector.

But 2019 deal-making has also been notable for another critical piece in the cell and gene therapy modality: manufacturing. Therapeutic cells and genes are unique products requiring special scale, and technical and logistical considerations

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Intelligence

More from In Vivo

Digital Transformation At The FDA: Generative AI Set To Transform Drug Review Process

 
• By David Wild

The FDA plans to implement generative AI for drug reviews by 30 June 2025, enhancing efficiency and potentially accelerating approval processes. Discussions with OpenAI about AI integration are ongoing.

Deals Shaping The Industry, April 2025

 
• By In Vivo Team

An interactive look at pharma, medtech and diagnostics deals made during April 2025. Data courtesy of Biomedtracker.

Plans For London Cancer Hub Promises New Destination For Biotech Innovation

 
• By Jo Shorthouse

Plans have been submitted for a £1bn development in London that can home biotech companies and encourages cross collaboration with the Institute of Cancer Research. In Vivo took an exclusive tour of the UK’s prospective new cancer innovation district.